About Us> Our Team

Getting It Done
to Improve Lives

Our team combines deep science expertise with an entrepreneurial “get it done” mindset. Our team has worked on Phase 3 trials for cardiometabolic medicines like ertuglifozin, sacubitril/valsartan, ezetimibe, vildagliptin; anti-cancer agents like ixazomib, tucatinib, and tagraxofusp; and new modalities including gene therapy for hemophilia and Duchenne’s Muscular Dystrophy. With our know-how, passion, and sense of urgency, we work every day toward a single goal: to generate definitive human proof-of-concept data and streamline clinical development for assets where we see a clear path to becoming a drug.

About Us > Our Team

Our Board of Directors

Brian Hubbard, Ph.D.

CEO, Anji Pharmaceuticals

Yiwei Zong, Ph.D.

COO, Anji Pharmaceuticals

Jun Mao, Ph.D.

Founder, JMCR Partners

Jason Wu

Partner, Fenghe Group

Lin Sun

Founding Partner, CR Capital

For partnerships, investment opportunities, or to learn more about our work, contact us.